Clinical Trials of Ticlopidine in Patients with Intermittent Claudication

  • Lars Janzon

Abstract

Atherosclerosis is the main pathophysiologic process behind peripheral arterial disease (PAD).1 Like other atherosclerotic manifestations, PAD is more common in old people than young and more common in men than women. The clinical spectrum of PAD ranges from an asymptomatic stage with weak leg arterial pulsations, a femoral bruit, or an abnormal systolic arm-ankle pressure gradient, to a symptomatic stage with intermittent claudication, rest pain, and gangrene. Depending on different clinical criteria and varying methods of assessing leg blood flow, the prevalence of PAD varies from one study to another. Several publications have presented prevalence estimates of intermittent claudication as being 2% in middle-aged men and 1% in middle-aged women.2–4 Study findings by Reunanen et al.2 support the clinical experience that PAD is becoming more common in women. Among 30–39-year-olds in that study, the prevalence of intermittent claudication was twice as high in women as in men.

Keywords

Placebo Cholesterol Ischemia Diarrhea Smoke 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Strandness DE Jr. Peripheral Arterial Disease. Boston, Little Brown, 1969.Google Scholar
  2. 2.
    Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982; 211: 249–256.PubMedCrossRefGoogle Scholar
  3. 3.
    Hughson WG, Mann J, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J 1978; 1: 1379–1381.PubMedCrossRefGoogle Scholar
  4. 4.
    Isacsson S-O. Venous occlusion plethysmography in 55-year-old men. A population study in Malmö, Sweden (thesis). Acta Med Scand 1972; 191: 537.Google Scholar
  5. 5.
    Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart and legs. The Framingham study. JAMA 1972; 221: 661–666.PubMedCrossRefGoogle Scholar
  6. 6.
    Janzon L, Bergentz S-E, Ericsson BF, Lindell SE. The arm-ankle pressure gradient in relation to cardiovascular risk factors in intermittent claudication. Circulation 1981; 63 (6): 1339–1341.PubMedCrossRefGoogle Scholar
  7. 7.
    Ruckley CV. Claudication. Br Med J 1986; 292: 970–971.CrossRefGoogle Scholar
  8. 8.
    Strandness D Jr, Stahler C. Arteriosclerosis obliterans. JAMA 1966; 196: 1–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Kannel WB, Shurtleff D. The natural history of arteriosclerosis obliterans. Cardiovasc Clin 1971; 37: 3.Google Scholar
  10. 10.
    Tillgren C. Obliterative disease of the lower limbs. II. A study of the cause of the disease. Acta Med Scand 1965; 178: 103.PubMedCrossRefGoogle Scholar
  11. 11.
    Silbert S, Zazeela H. Prognosis in arteriosclerotic peripheral vascular disease. JAMA 1958; 166: 186.Google Scholar
  12. 12.
    Boyd AM. The natural course of arteriosclerosis of the lower extremities. Proc Roy Soc Med 1962; 55: 591.PubMedGoogle Scholar
  13. 13.
    Källerö KS. Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography. A ten year follow-up study. J Chronic Dis 1981; 34: 455–462.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilhelmsson C, Vedin JA, Elmfeldt D, Tibblin G, Whilhelmsen L. Smoking and myocardial infarction. Lancet 1975; 1: 415.PubMedCrossRefGoogle Scholar
  15. 15.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562.Google Scholar
  16. 16.
    Coronary Heart Disease—Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–374.CrossRefGoogle Scholar
  17. 17.
    Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301–308.PubMedCrossRefGoogle Scholar
  18. 18.
    Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982; 35: 740–743.PubMedCrossRefGoogle Scholar
  19. 19.
    Stiegler H, Hess H, Mietaschk A, Trampisch H-J, Ingrisch H. Einfluss von Ticlopidin auf die periphere obliterierende arteriopathie. Dtsch Med Wschr 1984; 109: 1240–1243.PubMedCrossRefGoogle Scholar
  20. 20.
    Arcan JC, Blanchard JF, Boissel JP, Destors JM, Panak EA. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39 (9): 802–811.PubMedCrossRefGoogle Scholar
  21. 21.
    Ellis DJ. Treatment of intermittent claudication with ticlopidine. Abstract addendum. International Committee on Thrombosis and Haemostasis 32nd Annual Meeting and the Mediterranean League Against Thromboembolic Diseases, 9th Congress. Jerusalem, June 1–6, 1986.Google Scholar
  22. 22.
    Cloarec M, Caillard PH, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Thromb Res 1986; 6: 160.Google Scholar
  23. 23.
    Katsumara T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Angiology 1982; 33 (6): 357–367.CrossRefGoogle Scholar
  24. 24.
    Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Heamost 1989; 62 (2): 681–685.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1993

Authors and Affiliations

  • Lars Janzon

There are no affiliations available

Personalised recommendations